• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Medical Devices

  • Print
  • Share
  • E-mail

In Vitro Diagnostic Glucose Test System; Final Guidance for Industry

PDF Printer Version

 

 

Document issued on: July 6, 1998

CDRH Logo

U.S. Department Of Health And Human Services
Food and Drug Administration
Center for Devices and Radiological Health

Chemistry Toxicology and Hematology Branch
Division of Clinical Laboratory Devices
Office of Device Evaluation


Preface

Public Comment

Comments and suggestions may be submitted at any time for Agency consideration to, Joseph L. Hackett, Ph.D., Division of Clinical Laboratory Devices, HFZ-440, 9200 Corporate Blvd, Rockville, MD 20850. Comments may not be acted upon by the Agency until the document is next revised or updated. For questions regarding the use or interpretation of this guidance contact Joseph L. Hackett, Ph.D., at 301 594-3084.

Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 1105 to identify the guidance you are requesting.

Guidance Document

Device: In Vitro Diagnostic Glucose Test System

  1. Device Description

    Common Name (s): Glucose Test System

    Class: II

    Classification Panel: Clinical Chemistry (75)

    Product Codes:

    CFW, Copper Reduction, Glucose
    JIL, Enzymatic Method, Glucose (Urinary, Non-quantitative)
    CGD, Ferricyanide, Glucose
    LFR, Glucose Dehydrogenase, Glucose
    CGA, Glucose Oxidase, Glucose
    CFR, Hexokinase, Glucose

    Regulation numbers,: 21 CFR 862.1345

    A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids.

  2. Indications for Use

    Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell tumors..

  3. Specific Performance Characteristics

    1. PreClinical/Laboratory/In Vitro Studies

      The following eight performance characteristics (#1 Method Comparison - #8 Expected Values) should be included in the submission. Data should be provided that supports the use of the device with the specimen type(s) that are claimed to be appropriate for analysis:

      1. Method Comparison
        -slope, intercept
        -correlation coefficient
        -range of samples tested
        - standard error of the estimate
        -bias and bias plot
        -number of samples tested
        -plot of the data
      2. Precision
        -within-run (assay, and
        -between-run (assay), or
        -total
        -mean(s), standard deviation (s), and coefficient(s) of variation
      3. Linearity
        -recovery, dilution, etc.
      4. Sensitivity
        -minimum detection limit, or
        -analytical sensitivity
      5. Interferences
        -endogenous, e.g., bilirubin, hemoglobin, lipids, etc.
        -exogenous, e.g., drugs, anticoagulants, etc.
      6. Stability Summary
        -calibration interval
        -quality control interval
        -quality control materials
        -calibration materials
      7. Software
        -validation information
        -certification information
      8. Expected Values
        -literature reference (s), reference interval, or
        -population study, reference interval,
        -medical decision point(s) and/or
        -critical decision point(s)
    2. Clinical Studies

      A method comparison study as described above, comparing performance with that of the predicate device as well as an appropriate reference method should be conducted to demonstrate substantial equivalence. A statistically significant sample of patients from a population representing the proposed intended use should be included in the study, spanning the appropriate assay range.

    3. Total Measurement Error at selected decision points should be calculated and reported.
  4. Labeling Considerations:

    Refer to 21 CFR 809.10.

    Other: For a multi-purpose instrument used for diagnostic purposes refer to 21 CFR 809.10 (b) (1),(2),(6),(14),and (15).

    Checklist

    Instructions: Use this checklist for premarket notification for Chloride Test System as a guide in preparing your submission.

      
    Truthful and Accurate statement verbatim as per 21 CFR 807.87(j). 
    510(k) summary or statement per 21 CFR 807.92 or 21 CFR 807.93 respectively. 
    Indications for use on a separate page. 
    Labeling for in vitro diagnostic products (21 CFR 809.10 (b) 
    Pre-Clinical Data:
    Interference Studies
     
    Linearity Studies
     
    Precision studies at medical decision levels
     
    Clinical Data (method comparison) 


REFERENCES:

Methodologies to assist sponsors in establishing the specific performance characteristics addressed in part III of this document may be obtained using NCCLS documents or one of the following references:

Carey RN and Garber CC: Evaluation of Methods in Clinical Chemistry - theory, analysis, and correlation; Kaplan LA and Pesce AJ (eds), CV Mosby Company, St. Louis, 1984.

Koch DD and Peters T: Selection and Evaluation of Methods in Tietz Textbook of Clinical Chemistry (Burtis CA and Ashwood ER, WKB Saunders Co, Philadelphia, 1994.